![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2025
Holch, Julian Walter 
ORCID: https://orcid.org/0000-0002-4755-0179; Ohnmacht, Alexander J.; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Weiss, Lena ORCID: https://orcid.org/0000-0002-8101-3529; Probst, Victoria ORCID: https://orcid.org/0009-0008-8038-7351; Stahler, Arndt ORCID: https://orcid.org/0000-0003-1041-0137; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank ORCID: https://orcid.org/0000-0001-5575-1010; Link, Hartmut ORCID: https://orcid.org/0000-0002-9659-0265; Höffkes, Heinz-Gert; Moehler, Markus; Modest, Dominik Paul; Menden, Michael P. und Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321
(2. Mai 2025):
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters.
In: European Journal of Cancer, Bd. 220, 115388
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-4755-0179; Ohnmacht, Alexander J.; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Weiss, Lena ORCID: https://orcid.org/0000-0002-8101-3529; Probst, Victoria ORCID: https://orcid.org/0009-0008-8038-7351; Stahler, Arndt ORCID: https://orcid.org/0000-0003-1041-0137; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank ORCID: https://orcid.org/0000-0001-5575-1010; Link, Hartmut ORCID: https://orcid.org/0000-0002-9659-0265; Höffkes, Heinz-Gert; Moehler, Markus; Modest, Dominik Paul; Menden, Michael P. und Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321
(2. Mai 2025):
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters.
In: European Journal of Cancer, Bd. 220, 115388
[PDF, 1MB]
2018
Holch, Julian W.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Scholz, Michael; Müller, Sebastian; Link, Hartmut; Rost, Andreas; Höffkes, Heinz-Gert; Moehler, Markus; Lindig, Reinhard Udo; Miller-Phillips, Lisa; Kirchner, Thomas; Jung, Andreas; Einem, Jobst C. von; Modest, Dominik Paul und Heinemann, Volker
(2018):
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
In: International Journal of Cancer, Bd. 142, Nr. 5: S. 1047-1055